Cytomegalovirus peptide-Major Histocompatibility Complex (CMV pMHC) (CMV pMHC)

The Cytomegalovirus peptide-Major Histocompatibility Complex (CMV pMHC) is a molecular assembly comprising a viral peptide, typically derived from the immunodominant pp65 or IE1 proteins, non-covalently bound within the peptide-binding groove of a Major Histocompatibility Complex (MHC) molecule on the cell surface [2, 11]. This complex serves as the critical 'fingerprint' that allows the adaptive immune system, specifically CD8+ cytotoxic T lymphocytes (CTLs), to identify and eliminate CMV-infected cells through T-cell receptor (TCR) recognition [3, 12]. CMV has developed sophisticated immune evasion strategies by encoding proteins like US2, US3, US6, and US11, which actively disrupt the assembly, transport, and surface expression of these pMHC complexes to avoid immune detection [9, 14]. Therapeutic targeting of CMV pMHC is a major focus in treating CMV reactivation in immunocompromised individuals, such as transplant recipients, using virus-specific T-cell (VST) therapies, TCR-engineered T cells, or TCR-like antibodies [5, 10]. Additionally, these complexes are investigated for cancer immunotherapy, where CMV-specific T cells can be redirected to attack tumors decorated with CMV peptides [1, 8]. The high prevalence of specific HLA alleles, such as HLA-A*02:01, makes certain pMHC combinations attractive targets for developing precision immunotherapies and diagnostic monitoring tools [3, 13].

Other names

CMV peptide-HLA complexCMV antigen-MHC complexHLA-presented CMV antigenHCMV peptide-MHC complexMHC-I-CMV peptide complexCMV epitope-MHC complex

Therapeutic agents targeting this complex operate through the selective recognition of viral peptides (such as pp65-derived NLVPMVATV) presented within the MHC groove by engineered T-cell receptors (TCRs) or TCR-mimetic antibodies [3, 8]. This binding event triggers cytotoxic T-lymphocyte (CTL) activation, leading to the targeted destruction of infected cells via the release of perforin and granzymes or through antibody-dependent cellular cytotoxicity (ADCC) [5, 10].